Health Care · Pharmaceutical Preparations

VRTX Vertex Pharmaceuticals SEC Filings & Insider Trading Activity 2026

company
CIK 875320142 filings
Nasdaq 100
S&P 500

VRTX at a glance

Vertex Pharmaceuticals (VRTX, SEC CIK 875320) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Vertex Pharmaceuticals (VRTX) reported revenue of $12.0 billion (up 8.9% from FY2024) and net income of $4.0 billion. Diluted EPS was $15.32.
  • As of September 30, 2026, 50 institutional investment managers tracked by SignalX reported holding Vertex Pharmaceuticals (VRTX) shares worth $52.1 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Thornberry Nancy on November 16, 2026 of 1,000 shares at $547.86 per share.
  • In the last 90 days, VRTX insiders reported 0 open-market purchases ($0) and 4 open-market sales ($15.4M) on Form 4, a net sale of $15.4M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$12.0B
+8.9% vs prior year
Insiders · 90 days
0 buys · 4 sells
Net −$15.4M
13F holders
50 funds
$52.1B · −3 vs prior quarter
Latest 8-K
Nov 2, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Management Discussion & Analysis

  • Revenue $12.0B in 2025, up 9% YoY from $11.0B in 2024; TRIKAFTA/KAFTRIO sales $10.3B (1% increase), ALYFTREK $837.8M launched in 2025
  • Operating margin approx. 34.7% in 2025 vs 13.8% cost of sales (13.8% of net product revenues), slight improvement from 13.9% in 2024; R&D + SG&A expenses $5.7B up from $5.1B
  • Best performing segment: TRIKAFTA/KAFTRIO revenues $10.31B (+1%); Worst: Newly launched CASGEVY $115.8M and JOURNAVX $59.6M, small but growing
  • Cash, cash equivalents, marketable securities increased to $12.3B in 2025 from $11.2B in 2024; repurchased shares partially offset; R&D expenses $3.91B (+8%), cost of sales $1.65B (+8%)
  • 2026 Outlook: Continued CF revenue growth led by ALYFTREK globally, increased CASGEVY and JOURNAVX revenues; pipeline regulatory submissions expected H1 2026; watch ongoing royalty dispute on ALYFTREK royalty rate

Business Overview

  • Core business model: Biopharmaceutical company focused on developing and commercializing transformative medicines
  • Emphasis on enhanced cybersecurity governance with dedicated CISO and quarterly Board updates
  • Cybersecurity led by CISO with 35+ years’ experience, including federal advisory roles, highlighting heightened focus on cyber risk
  • Cybersecurity team holding top certifications conducts regular vulnerability scans, penetration tests, and threat intelligence analysis
  • Cybersecurity risk oversight integrated into executive management reporting chain up to CEO, reflecting strategic prioritization

Risk Factors

  • Regulatory risk: Impact of Colorado PDAB affordability review on TRIKAFTA pricing with potential upper payment limits under the 2023 state program
  • Macroeconomic risk: Ex-U.S. reimbursement delays and government cost-containment efforts impacting pricing and revenue in various international markets
  • Operational risk: CASGEVY manufacturing cost significantly higher as a percentage of revenue versus CF medicines, with complex cell collection and administration processes
  • Competitive risk: Pressure from lower-cost and advanced competitors in acute and peripheral neuropathic pain markets threatening uptake of JOURNAVX
  • Financial risk: Concentrated revenue dependence on CF medicines, exposing business to risks from manufacturing, safety, market acceptance, and pricing challenges

AI summary of the VRTX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added risk: Crinetics integration, including potential failure to retain key employees or realize synergies
  • Most materially updated risk: PALSONIFY and atumelnant may miss expected commercial performance or development timelines
  • Regulatory risk: povetacicept accelerated-approval review carries a November 30, 2026 PDUFA target action date
  • Operational risk: Integration activities could disrupt ongoing business and divert management attention
  • Financial risk: Crinetics acquisition benefits depend on future revenues from PALSONIFY and atumelnant

Management Discussion & Analysis

  • Q3 revenue $3,440.8M, up 12% YoY from $3,076.4M
  • Cost-of-sales margin 15.3% vs 13.5% YoY; total costs and expenses $2,727.9M, up 44%
  • Best product: ALYFTREK revenue $705.8M, up 186%; weakest: TRIKAFTA/KAFTRIO $2,436.9M, down 8%
  • Cash, equivalents and securities $9,821.2M, down 20% from $12,320.4M; nine-month operating cash flow $3,196.6M
  • Crinetics acquisition consumed $9.1B net cash; $4.5B term loan increased future interest expense and debt repayments through 2029

AI summary of the VRTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 2, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 and nine-month 2026 consolidated financial results announced for periods ended September 30, 2026
  • Detailed revenue, earnings, guidance and operating metrics contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $3.44B, up 12%, supported by CF growth and diversification into CASGEVY, JOURNAVX, and PALSONIFY
  • FY2026 revenue guidance raised to $13.15B-$13.25B, with CASGEVY and JOURNAVX expected to contribute at least $500M combined
Filed Oct 20, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Daniel Brennan appointed director on October 20, 2026, expanding the Board from 10 to 11 members
  • Audit and Finance Committee addition strengthens financial oversight with former Boston Scientific CFO experience
Filed Sep 1, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Jonathan Poole becomes CFO January 1, 2027, succeeding Charles Wagner, who remains Executive Vice President and COO
  • Poole brings Vertex finance experience since March 2020 and prior biotech CFO roles

AI summaries of VRTX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for VRTX

Don't miss the next VRTX filing

  • Alerts as it files. A push when VRTX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut VRTX, by share count.
  • Ask anything. An AI agent that reads every VRTX filing and answers with sources.

VRTX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Thornberry NancySellNov 16, 2026$547.86
Bhatia Sangeeta N.SellNov 16, 2026$547.86
WAGNER CHARLES F JRSellNov 12, 2026$547.87
Kewalramani ReshmaSellNov 6, 2026$531.53
Brennan Daniel J.AOct 20, 2026$503.47
SACHS BRUCE IAOct 15, 2026$512.44
Garber Alan MAOct 15, 2026$512.44
van Grunsven JasperASep 8, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$11.0B$12.0B
Operating Income--$232.9M$4.2B
Net Income$3.6B-$535.6M$4.0B
Op. Margin--2.1%34.8%
Net Margin--4.9%32.9%
Balance Sheet
Total Assets$22.7B$22.5B$25.6B
Equity-$16.4B$18.7B
ROE--3.3%21.2%
Per Share
EPS$13.89$-2.08$15.32
Cash Flow
Operating CF--$492.6M$3.6B
CapEx$200.4M$297.7M$437.6M

Source: XBRL data in Vertex Pharmaceuticals (VRTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate VRTX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
VRTX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202650$52.11B
Q2 202653$49.90B
Q1 202652$43.45B
Q4 202550$44.36B
Q3 202550$38.95B
Q2 202548$42.58B
Q1 202548$35.54B
Q4 202445$23.98B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 396 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

VRTX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 16, 2026--
4Nov 10, 2026--
10-QNov 3, 2026Analysis
8-KNov 2, 2026Analysis-
4Oct 22, 2026--
8-KOct 20, 2026Analysis-
4Oct 19, 2026--
4Oct 19, 2026--
4Sep 10, 2026--
4Sep 1, 2026--
8-KSep 1, 2026Analysis-
4Aug 31, 2026--
10-QAug 4, 2026Analysis
8-KAug 3, 2026Analysis-
4Jul 23, 2026--
4Jul 23, 2026--
4Jul 17, 2026--
4Jul 17, 2026--
4Jul 7, 2026--
4Jul 7, 2026--
8-KJul 7, 2026Analysis-
4Jul 6, 2026--
4Jun 30, 2026--

Related Health Care companies

All Health Care →

VRTX SEC filings: frequently asked questions

Are VRTX insiders buying or selling?

In the last 90 days, Vertex Pharmaceuticals (VRTX) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $15.4 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold VRTX stock?

As of September 30, 2026, the largest Vertex Pharmaceuticals (VRTX) holders among the 13F filers tracked by SignalX were BlackRock ($12.4 billion), Vanguard Capital Management LLC ($8.7 billion), State Street Corp ($6.3 billion), Invesco Ltd ($4.3 billion), JPMorgan Chase & Co ($3.0 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was VRTX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Vertex Pharmaceuticals (VRTX) reported revenue of $12.0 billion (up 8.9% from FY2024) and net income of $4.0 billion. Diluted EPS was $15.32. The figures come from the XBRL data in the 10-K.

What are the main risks in VRTX's latest 10-K?

In the 10-K filed February 13, 2026, Vertex Pharmaceuticals (VRTX) flagged: Regulatory risk: Impact of Colorado PDAB affordability review on TRIKAFTA pricing with potential upper payment limits under the 2023 state program. Macroeconomic risk: Ex-U.S. reimbursement delays and government cost-containment efforts impacting pricing and revenue in various international markets. (AI summary of the Risk Factors section.)

What did VRTX report in its latest 8-K?

Vertex Pharmaceuticals (VRTX) filed an 8-K on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 and nine-month 2026 consolidated financial results announced for periods ended September 30, 2026.

What are the latest VRTX SEC filings?

Vertex Pharmaceuticals (VRTX) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 18, 2026.

What is VRTX's SEC CIK number?

Vertex Pharmaceuticals (VRTX)'s SEC Central Index Key (CIK) is 875320. EDGAR lists every VRTX filing under that number.

Ask anything about VRTX

The research agent reads VRTX's filings, financials, insider trades and 13F holders, then answers with sources.